🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Micron, Nike, Citrix Rise Premarket; General Mills Falls

Published 12/21/2021, 07:51 AM
Updated 12/21/2021, 07:52 AM
© Reuters.
FDX
-
GIS
-
CTXS
-
MU
-
NKE
-
US90274J5618=UBSS
-
MRNA
-
NKLA
-

By Peter Nurse 

Investing.com -- Stocks in focus in premarket trade on Tuesday, December 21st. Please refresh for updates.

  • Nike (NYSE:NKE) stock rose 3.7% after sales of its shoes and apparel in North America, the company’s largest market, rose 12% year-on-year, offsetting a 20% slump in the company’s sales in China.

  • Micron (NASDAQ:MU) stock rose 8.5% after a solid start to the chipmaker's financial year, driven by strong demand for its memory and storage chips, led it to promise a record year of sales with “solid profitability”.

  • Nikola (NASDAQ:NKLA) stock rose 2.9% after the electric-truck maker agreed to pay $125 million to the Securities and Exchange Committee to settle charges that it defrauded investors, removing an element of uncertainty over the stock.

  • FedEx (NYSE:FDX) stock rose 1.5% after JPMorgan named the delivery company as one of its top picks for 2022, seeing nearly 30% upside.

  • General Mills (NYSE:GIS) stock fell 3.5% after the food retailer missed its quarterly earnings estimates, citing higher input costs and supply chain disruptions. That said, it raised its full-year sales forecast, boosted by strong demand for snacks and baking products as the pandemic-induced at-home cooking boom held strong.

  • Citrix Systems (NASDAQ:CTXS) stock rose 9.2% following a Bloomberg report that said that activist investor Elliott Management and Vista Equity Partners are considering a joint bid for the cloud computing company.

  • Rite Aid (NYSE:RAD) stock rose 4.8% after the pharmacy chain recorded a quarterly profit, instead of the expected loss, and announced the closure of over 60 stores to generate annual savings of around $25 million.

  • Moderna (NASDAQ:MRNA)stock rose 0.3% after CEO Stephane Bancel told a Swiss newspaper that work to tailor its Covid-19 vaccine to protect against the Omicron variant could begin within a few weeks, and that only minor adjustments would be needed.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.